Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BI 765423
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Details : BI 765423 is the first-in-class IL-11 inhibitor antibody, which is being developed in partnership with Enleofen for the treatment of fibrotic diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : BI 765423
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enx108A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,000.0 million
Deal Type : Partnership
Details : Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $1,000.0 million
January 09, 2020
Lead Product(s) : Enx108A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,000.0 million
Deal Type : Partnership
Reset All
